NanoVation Therapeutics™

Join Us for NanoVation' First Webinar! 📅 Tuesday, September 24th | 5:00 PM CET | 11:00 AM EST | 8:00 AM PST   NanoVation Therapeutics (NTx) is excited to announce our upcoming webinar in collaboration with the European Technology Platform on Nanomedicine (ETPN Association). Learn about the latest advancements in lipid nanoparticle (LNP) technologies, focusing on enabling nucleic acid delivery beyond the liver.   Speakers: 🎤 Pieter Cullis: Historical Perspective on LNPs 🎤 Dominik Witzigmann, PhD: Next Generation LNPs 🎤 Laura Evgin: T Cell Applications   💡 Don't miss out—register now and join us for an interactive Q&A session! 👉 Register here: https://shorturl.at/ydL5L   #NanoVationTherapeutics #ETPN #Nanomedicine #LNPs #Webinar #Innovation #Biotech

Our Board Chair, Pieter Cullis, will be speaking at the Ribo Club Annual Meeting hosted by RNA Canada ARN (formerly called Canadian Consortium of RNA Researchers), in Ottawa, from September 30 to October 4.    Additionally, our Director of RNA, Bruno Fonseca, PhD, will also be participating. This is a prime opportunity to dive into NTx's upcoming milestones and learn how we're at the forefront of groundbreaking advancements in genetic medicines, nucleic acids, and lipid nanoparticles.   Join us in Ottawa to connect, collaborate, and innovate together! Let's shape the future of biotech.   #NanoVationTherapeutics #RiboClub #GeneticMedicines #NucleicAcids #LipidNanoparticles #Innovation  #Biotech

🌐 Focus on Science: TOP mRNA Binding to LARP1    Today we highlight a significant publication from our RNA Director, Bruno Fonseca, PhD, titled "Capturing the Mechanism Underlying TOP mRNA Binding to LARP1," co-authored with Kevin Cassidy, Roni Lahr, Jesse C. Kaminsky, and others.    🔬This study delves into the role of the RNA-binding protein La-related protein 1 (LARP1) in ribosome biosynthesis. By characterizing the dynamics of DM15-TOP recognition, the study reveals crucial insights into this fundamental biological process, opening up unique opportunities for further pharmaceutical development.    🧬 At NanoVation Therapeutics, we are building on this foundational work to advance our technologies enabling safe and efficient genetic medicines. This research perfectly aligns with our mission to develop innovative solutions for the next generation of therapies.    Discover more about this impactful research here:  https://lnkd.in/d2CphAwx   #RNA #Pharmacology #Biotechnology #NTx #LipidNanoparticles #NanoVationTherapeutics #genetherapy  #Nucleicacid 

🏆  Our Chief Intellectual Property Officer, Wendy Lamson, has been listed on the prestigious 2024 IAM 300 list, which recognizes the world's leading IP strategists. This is a significant honor and a testament to Wendy's exceptional expertise and contributions to the field. We are proud to have Wendy on our team.    NanoVation has developed a leading one-stop-shop IP portfolio covering specialty (ionizable) lipids, LNP compositions as well as mRNA modifications. Our flagship long-circulating LNP (lcLNP™) technology enables functional nucleic acid delivery to extrahepatic tissues such as the bone marrow.   For more details, you can check out the announcement here: https://shorturl.at/RcGog Join us in congratulating Wendy on this well-deserved recognition!   #NanoVationTherapeutics #IPStrategy #IAM300 #LNP #RNA #Innovation #Biotech

🔬 Exciting Milestone for NanoVation Therapeutics!    We are thrilled to announce that our first chemistry paper, stemming from the innovative research at NanoVation, has just been published in the Journal of Organic Chemistry!   This publication marks a significant achievement for our team as we continue to push the boundaries of science and innovation. The paper, authored by Ardalan Nabi N. D. Prasad Atmuri, Ph.D., Fariba Saadati, Huy Tran, Ph.D., Marco Ciufolini and Co, explores the Claisen self-condensation of lactones under Mukaiyama conditions using TiCl4 and triethylamine. The study reveals that this method can safely and efficiently produce dihydroxyketones, which are crucial for synthesizing ionizable lipids used in the delivery of nucleic acid therapeutics. This work introduces a concise, economical, and scalable route, avoiding more technically challenging reaction sequences.   Check out the full paper here: https://lnkd.in/dhnqEa9r   #NanoVation #ScientificResearch #OrganicChemistry #Innovation #ScienceMilestone #ResearchAndDevelopment #JournalPublication

Join Our Team at NanoVation Therapeutics! Are you collaborative and detail-oriented professional looking to make a significant impact in a dynamic and innovative environment? We are looking for an Accountant to join our finance team at NTx.   Key Responsibilities: 💼 Full-cycle accounting to ensure accuracy and compliance with financial standards. 💼 Financial reporting, providing insights to support decision-making. 💼 Supporting a variety of accounting projects.   What We’re Looking For: 🎓 You are working toward your CPA. 🎓 You have excellent analytical and problem-solving skills with a keen eye for detail. 🎓 You are a strong team player who works collaboratively in a fast-paced environment.   Apply today to support our mission to innovate and excel in the life sciences industry!   Full details of the role can be found here: https://shorturl.at/w9EGM   #AccountingJobs #FinanceCareers #LifeSciences #NanoVation   

Recently, our CEO, Dominik Witzigmann, PhD gave an insightful interview at the Applied Biophysics Forum in Drug Delivery, held in Copenhagen.    Discover more about the latest advancements and news from NTx here: https://lnkd.in/drzaQMKF   #GeneTherapy #LipidNanoparticles #RNA #Biophysics #Characterization #RationalDesign #NanoVationTherapeutics  

Join Our Team at NanoVation Therapeutics!    We’re hiring a Logistics Coordinator! Ready to make an impact in the life sciences industry? Join our dynamic team and help revolutionize healthcare.   🔗 https://shorturl.at/uPybc Be a part of the NTx adventure!

Focus on New NanoVators: Welcoming Our Latest Talents at NanoVation Therapeutics (NTx)   We are thrilled to introduce the latest additions to our NTx family! Please join us in welcoming Ariane Miriam Nissenbaum, Atul Kaushik Rangadurai, PhD, Ardalan Nabi, and Tony Cheung. Each of them brings their unique personality, passion and expertise in RNA, Chemistry and Finance to our team. We are excited to see the innovative contributions they will make.   Want to join us in developing tomorrow's genetic medicines: https://lnkd.in/ePpS-_tM

NTx at the Biointerfaces International Conference 2024 (BIC) 2024   We are pleased to announce that NTx will be participating in the BIC from August 20-23 in  Switzerland.   Our Scientific Advisor, Prof. Molly Stevens, (UK), will be delivering a keynote address on "Designing and Translating Materials for Advanced Therapeutics and Biosensing."   Additionally, our CSO, Dr. Jayesh Kulkarni, will present two talks on mRNA Therapeutics.   We look forward to contributing to and engaging with the scientific community at BIC 2024.   #Biotech #Therapeutics #mRNATherapeutics #Innovation #mRNA #LPN